The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Compounds having the chemical formula 1, ##STR00001##
a method for producing the compounds of chemical formula 1, a pharmaceutical composition comprising same, and use thereof as a GPR120 agonist for prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Compounds having the chemical formula 1, ##STR00001##
a method for producing the compounds of chemical formula 1, a pharmaceutical composition comprising same, and use thereof as a GPR120 agonist for prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Provided are a methane-production inhibitor capable of inhibiting methane production for a long period of time, and a method for inhibiting methane production using the composition. A methane-production inhibitor composition contains one or more compounds selected from compounds represented by formula [I] as an effective ingredient, and a method for inhibiting methane production uses the composition.

##STR00001##

(In formula [I], X represents an —OR.sub.1 group, a hydroxyl group, or a halogen atom, Y represents an —OR.sub.2 group or an —SO.sub.2R.sub.3 group, R.sub.1 represents a benzoyl group, R.sub.2 represents a methylsulfonyl group or a chloromethylsulfonyl group, and R.sub.3 represents a chloromethyl group or a hydroxymethyl group.)

Provided are a methane-production inhibitor capable of inhibiting methane production for a long period of time, and a method for inhibiting methane production using the composition. A methane-production inhibitor composition contains one or more compounds selected from compounds represented by formula [I] as an effective ingredient, and a method for inhibiting methane production uses the composition.

##STR00001##

(In formula [I], X represents an —OR.sub.1 group, a hydroxyl group, or a halogen atom, Y represents an —OR.sub.2 group or an —SO.sub.2R.sub.3 group, R.sub.1 represents a benzoyl group, R.sub.2 represents a methylsulfonyl group or a chloromethylsulfonyl group, and R.sub.3 represents a chloromethyl group or a hydroxymethyl group.)

The present specification relates to a compound including an aromatic ring, a polymer electrolyte membrane including the same, a membrane-electrode assembly including the polymer electrolyte membrane, a fuel cell including the membrane-electrode assembly, and a redox flow battery including the polymer electrolyte membrane.

The present specification relates to a compound including an aromatic ring, a polymer electrolyte membrane including the same, a membrane-electrode assembly including the polymer electrolyte membrane, a fuel cell including the membrane-electrode assembly, and a redox flow battery including the polymer electrolyte membrane.

Compounds having a structure of Formula I:

##STR00001##

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.11a, R.sup.11b, R.sup.11c, R.sup.11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.